Supernus

SUPN

29.7201.78% ( +0.520 )

Closed: Nov 13, 16:00:00 (EDT)

Supernus CEO to Participate in Fireside Chat at Jefferies Global Healthcare Conference
PUBT·Nov 10, 2026 at 01:34 PM
SUPN+1.78%
Is Supernus (SUPN) Undervalued After Joining The Nasdaq Composite?
Simplywall·Nov 10, 2026 at 07:21 AM
SUPN+1.78%.IXIC-0.91%
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
benzinga_article·Nov 9, 2026 at 04:30 PM
AMRO-14.06%CWH0.00%
Cantor Fitzgerald Sticks to Its Buy Rating for Supernus (SUPN)
Tip Ranks·Nov 4, 2026 at 03:46 PM
SUPN+1.78%
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday
benzinga_article·Nov 4, 2026 at 12:39 PM
- Top Wall Street financial institutions have updated their price targets, ratings, and outlooks for several prominent publicly traded companies. - Key adjustments include Piper Sandler raising Freshworks Inc to $15, Truist Securities upgrading Edwards Lifesciences Corp to Buy with a $113 target, and Morgan Stanley downgrading Flagstar Bank to Underweight. - Additional rating and target modifications involve firms such as BTIG, Cantor Fitzgerald, Needham, B of A Securities, and B. Riley Securities across various market sectors.
AMD-8.75%ATRC+1.54%
Cantor Fitzgerald maintains Supernus at Overweight, raises price target to $87 from $67
TradingView·Nov 4, 2026 at 10:04 AM
SUPN+1.78%
Supernus hits 52-week low
Market Movers·Nov 3, 2026 at 08:27 PM
SUPN+1.78%
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga_article·Nov 3, 2026 at 05:05 PM
ACB-1.00%BDMD-15.66%
Supernus Pharmaceuticals climbs 7% on Indivior merger completion
Market Movers·Nov 3, 2026 at 02:31 PM
SUPN+1.78%
Supernus Awards 100,000 Restricted Stock Units to Senior VP Padmanabh Bhatt
PUBT·Nov 2, 2026 at 09:12 PM
SUPN+1.78%
Supernus Pharmaceuticals Seeks Nasdaq Delisting Following Merger Completion
PUBT·Nov 2, 2026 at 03:51 PM
SUPN+1.78%
Supernus Names Tony Kingsley Board Chair Following Indivior Merger
PUBT·Nov 2, 2026 at 02:29 PM
INDV0.00%SUPN+1.78%
Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader | SUPN Stock News
StockTitan·Nov 2, 2026 at 06:18 AM
INDV0.00%SUPN+1.78%
Supernus Pharma | 8-K: FY2026 Q3 Revenue: USD 226.77 M
Earnings Watch·Oct 29, 2026 at 08:26 PM
SUPN+1.78%
SUPN: Record Q3 revenue and growth-product momentum; FY guidance raised ahead of merger close
Quartr·Oct 29, 2026 at 08:12 PM
INDV0.00%SUPN+1.78%